Question of Whether Tenofovir Disoproxil Fumarate/Emtricitabine Provides Protection Against Clinical Severity of Coronavirus Disease 2019
| Errataetall: |
CommentOn: Clin Infect Dis. 2023 May 24;76(10):1727-1734. - PMID 36861341 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 76(2023), 10 vom: 24. Mai, Seite 1735-1737 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Del Amo, Julia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
99YXE507IL |
|---|
| Anmerkungen: |
Date Completed 26.05.2023 Date Revised 10.10.2023 published: Print CommentOn: Clin Infect Dis. 2023 May 24;76(10):1727-1734. - PMID 36861341 Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciad086 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353673099 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353673099 | ||
| 003 | DE-627 | ||
| 005 | 20231226060540.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciad086 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1178.xml |
| 035 | |a (DE-627)NLM353673099 | ||
| 035 | |a (NLM)36861337 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Del Amo, Julia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Question of Whether Tenofovir Disoproxil Fumarate/Emtricitabine Provides Protection Against Clinical Severity of Coronavirus Disease 2019 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.05.2023 | ||
| 500 | |a Date Revised 10.10.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: Clin Infect Dis. 2023 May 24;76(10):1727-1734. - PMID 36861341 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Tenofovir | |
| 650 | 4 | |a confounding | |
| 650 | 4 | |a drug repurposing | |
| 650 | 4 | |a observational studies | |
| 650 | 7 | |a Tenofovir |2 NLM | |
| 650 | 7 | |a 99YXE507IL |2 NLM | |
| 650 | 7 | |a Emtricitabine |2 NLM | |
| 650 | 7 | |a G70B4ETF4S |2 NLM | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 76(2023), 10 vom: 24. Mai, Seite 1735-1737 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2023 |g number:10 |g day:24 |g month:05 |g pages:1735-1737 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciad086 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2023 |e 10 |b 24 |c 05 |h 1735-1737 | ||